Exploring Wellbeing Outcomes in Adolescents Using Bifidobacterium Longum, 1714™: a Prospective Open-Label Real-World Study

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age15-17
SponsorNovonesis

About this trial

The purpose of this study is to evaluate changes in self-reported wellbeing outcomes in adolescents. Bifidobacterium longum, 1714™ has previously been associated with beneficial effects on stress-related outcomes, sleep quality, subjective wellbeing and aspects of cognitive performance, however evidence in adolescents is limited. This study will evaluate changes in outcomes related to anxiety, sleep, fatigue, cognitive function and other wellbeing outcomes following daily consumption of Bifidobacterium longum, 1714™ under real-world conditions.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Aged 15-17 years at the time of study screening

Able and willing to provide informed consent or assent, with parental consent where applicable.

Enrolled in school or college at the time of screening

Participants must be able to read and understand English.

Disqualifiers

Pregnant, breastfeeding, or planning pregnancy during the study period

Known allergy or intolerance to any component of the study product

Pose a safety risk, or

Confound interpretation of study outcomes, as judged by the Investigator

Trial design

Design model

Single group

Treatments tested in this trial

  • Bifidobacterium longum, 1714™

    Dietary supplement

    1 capsule daily for 8 weeks

Treatment groups

150 Participants
are divided into 1 treatment group
Group A: Bifidobacterium longum, 1714™Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Change From Baseline to Week 4 in PROMIS Pediatric Anxiety CAT T-Score

Mean change from baseline to Week 4 in PROMIS Pediatric Anxiety Computer Adaptive Test (CAT) T-score, self-reported by adolescent participants. PROMIS Anxiety is a standardized T-score measure, with higher scores indicating greater anxiety symptom severity.

Time frame
Baseline to week 4.

Secondary outcomes

1

Change From Baseline in PROMIS Pediatric Anxiety CAT T-Score at Weeks 6 and 8

Mean change from baseline to Weeks 6 and 8 in PROMIS Pediatric Anxiety Computer Adaptive Test (CAT) T-score, self-reported by adolescent participants. Higher T-scores indicate greater anxiety symptom severity.

Time frame
Baseline to Weeks 6 and 8.
2

Change From Baseline in PROMIS Parent Proxy Anxiety CAT T-Score

Mean change from baseline to Weeks 4, 6 and 8 in PROMIS Parent Proxy Anxiety CAT T-score, as reported by parent participants. Higher T-scores indicate greater anxiety symptom severity.

Time frame
Baseline to Weeks 4, 6 and 8.
3

Change From Baseline in PROMIS Pediatric Cognitive Function CAT T-Score

Mean change from baseline to Weeks 4, 6 and 8 in PROMIS Pediatric Cognitive Function CAT T-score, self-reported by adolescent participants. Higher scores indicate better cognitive functioning.

Time frame
Baseline to Weeks 4, 6 and 8.
4

Change From Baseline in PROMIS Parent Proxy Cognitive Function CAT T-Score

Mean change from baseline to Weeks 4, 6 and 8 in PROMIS Parent Proxy Cognitive Function CAT T-score, as reported by parent participants. Higher scores indicate better cognitive functioning.

Time frame
Baseline to Weeks 4, 6 and 8.

Other outcomes

1

Change in Wearable-Derived Sleep Duration

Change over time in sleep duration derived from Garmin wearable device data collected throughout the study period. Sleep data will be collected passively and continuously during the run-in and intervention periods.

Time frame
Baseline through Week 8.
2

Change in Wearable-Derived Stress Metrics

Change over time in stress-related metrics derived from wearable device data collected throughout the study period. Stress measures will be collected passively and continuously during the run-in and intervention periods.

Time frame
Baseline through Week 8.
3

Change in Cognitive Performance Assessed by Verbal Paired Associates Learning (PAL)

Change from baseline in cognitive performance assessed using the electronic verbal Paired Associates Learning (PAL) task. The assessment is exploratory and not intended for diagnostic use.

Time frame
Baseline to Weeks 4, 6 and 8.
4

Study Product Compliance

Self-reported compliance with study product consumption, assessed as the number of days per week participants report taking the study product during the intervention period.

Time frame
Weekly during the 8-week intervention period.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: